- Home
- TC vs DRMA Comparison
TC vs DRMA Comparison
Compare TC & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- DRMA
- Stock Information
- Founded
- TC 2010
- DRMA 2014
- Country
- TC China
- DRMA United States
- Employees
- TC N/A
- DRMA N/A
- Industry
- TC Business Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- DRMA Health Care
- Exchange
- TC Nasdaq
- DRMA Nasdaq
- Market Cap
- TC 2.0M
- DRMA 1.7M
- IPO Year
- TC 2018
- DRMA 2021
- Fundamental
- Price
- TC $0.81
- DRMA $1.07
- Analyst Decision
- TC
- DRMA Strong Buy
- Analyst Count
- TC 0
- DRMA 1
- Target Price
- TC N/A
- DRMA $6.00
- AVG Volume (30 Days)
- TC 2.3M
- DRMA 85.2K
- Earning Date
- TC 11-29-2024
- DRMA 11-13-2024
- Dividend Yield
- TC N/A
- DRMA N/A
- EPS Growth
- TC N/A
- DRMA N/A
- EPS
- TC N/A
- DRMA N/A
- Revenue
- TC $14,107,804.00
- DRMA N/A
- Revenue This Year
- TC N/A
- DRMA N/A
- Revenue Next Year
- TC N/A
- DRMA N/A
- P/E Ratio
- TC N/A
- DRMA N/A
- Revenue Growth
- TC N/A
- DRMA N/A
- 52 Week Low
- TC $0.75
- DRMA $1.11
- 52 Week High
- TC $5.40
- DRMA $13.35
- Technical
- Relative Strength Index (RSI)
- TC 28.66
- DRMA 32.60
- Support Level
- TC $0.77
- DRMA $1.22
- Resistance Level
- TC $0.86
- DRMA $1.54
- Average True Range (ATR)
- TC 0.12
- DRMA 0.11
- MACD
- TC -0.00
- DRMA -0.02
- Stochastic Oscillator
- TC 6.26
- DRMA 3.53
About TC TuanChe Limited
TuanChe Ltd is an omnichannel automotive marketplace in China. The company operates in one operating segment of providing auto shows, special promotion events services, and virtual dealership, online marketing services, and others. It organizes auto shows, which aim at facilitating transactions between consumers and auto dealers that include auto dealers, automakers, and automotive service providers. It provides services through its online platform and offline events.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.